JPRN-jRCT2041210091进行中（未招募）1 期
A phase Ib, multicenter study of VOB560 in combination with MIK665 in patients with relapsed/refractory non-Hodgkin lymphoma, relapsed/refractory acute myeloid leukemia, or relapsed/refractory multiple myeloma
Hirano Takamitsu0 个研究点目标入组 15 人开始时间: 2021年10月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Diagnosis of one of the following hematologic malignancies:
- •- relapsed and/or refractory patients with non-Hodgkin lymphoma who have received >= 2 lines of therapy and who are not eligible for treatment with other regimens known to provide clinical benefit with radiographically measurable disease with a clearly demarcated nodal lesion at least 1.5 cm in its largest dimension or a target extra nodal lesion at least 1.0 cm in its largest dimension
- •- relapsed and/or refractory patients with MM treated with at least 3 prior regimens, including an IMiD, a proteasome inhibitor, and anti-CD38 antibody (if available) and not eligible for treatment with other regimens known to provide clinical benefit, as determined by the investigator. With measurable disease per the IMWG response criteria, as indicated by one or more of the following:
- •-Serum M-protein >= 0.5 g/dL, Urine M-protein >= 200 mg/24 hours
- •-For Patients who do not meet 1 of the 2 prior criteria:
- •Serum Free Light Chain (sFLC) >= 10 mg/dL (>= 100 mg/L) and an abnormal sFLC ratio (< 0.26 or > 1.65) as per the IMWG response criteria
- •In the dose expansion, at least 10 MM patients with documented 1q gain will be included.
- •- relapsed and/or refractory patients with Acute Myeloid Leukemia (AML), pathologically confirmed diagnosis as defined by the WHO Classification and with >= 5% blasts in bone marrow who have failed all conventional therapy and are deemed by the investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established therapeutic regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded).
排除标准
- •- History of severe hypersensitivity reactions to any ingredient of study treatment and/or their excipients.
- •- Systemic antineoplastic therapy (including cytotoxic chemotherapy, alpha-interferon, kinase inhibitors or other targeted small molecules, and toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of study treatment.
- •- High-risk patients for Tumor Lysis Syndrome according to Cairo et al 2010 criteria or local guidelines.
- •- Impaired cardiac function or clinically significant cardiac disease, or history or current diagnosis of ECG abnormalities indicating significant risk of safety
- •- For AML patients: Peripheral blast counts > 25,000 blasts / mm3. Patients can receive hydroxyurea to control the peripheral blast counts as long as hydroxyurea can be stopped at least 24 hours prior to obtaining PD biomarkers at screening/baseline. Hydroxyurea can be restarted after sampling if clinically indicated to control blasts prior to the start of study treatment markers.
研究者
相似试验
终止
1 期
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)Non-Hodgkin Lymphoma (NHL)Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)NCT04702425Novartis Pharmaceuticals37
进行中（未招募）
1 期
A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kd Inhibitor, in Relapsed or Refractory Follicular Lymphoma(CITADEL-203)MedDRA version: 21.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864Follicular LymphomaEUCTR2017-001624-22-ITINCYTE CORPORATIO120
进行中（未招募）
1 期
Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung.EUCTR2016-003609-32-GBBerGenBio ASA106
进行中（未招募）
1 期
A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the LungEUCTR2016-003609-32-ESBerGenBio AS48
进行中（未招募）
1 期
Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung.Previously Treated Advanced Adenocarcinoma of the LungMedDRA version: 20.0Level: LLTClassification code 10001160Term: Adenocarcinoma lungSystem Organ Class: 100000004864EUCTR2016-003609-32-NOBerGenBio ASA106